“I am very pleased to be joining the Matinas BioPharma team to lead the company’s initiatives as we work to advance our orally administered, encochleated broad-spectrum fungicidal and broad-spectrum aminoglycoside antibiotic drug formulations from clinical development toward commercialization to help treat patients with serious and life-threatening infections,” Mannino said in a prepared statement.
The company said Mannino’s field of expertise is artificial lipid-based structures for the formulation and delivery of biologicals and pharmaceuticals. He is a pioneer in the use of cochleate technology for these purposes, the company added.
“We have been working very closely with Dr. Mannino as a scientific adviser, and we are honored to officially welcome him as a member of our management team,” Roelof Rongen, CEO and president, said in a statement.
For the full story: